Find Your MAC! Add TransLabs as a preferred
source on Google
  • 4009 Hackney Springs Ln, Sachse, TX 75048
Inquire Now

Since You’re Already Here,

See Where Your Laboratory

May Be Losing Revenue!

Contact us

Related Articles

Your Lab May Be Losing Money Right Now!

Find out fast with a

No-Cost Revenue Audit.

Get In Touch

Schedule Free Demo

PAMA Clinical Lab Fee Schedule Updates

PAMA 2027 & Clinical Lab Fee Schedule Updates: What Independent & Reference Labs Must Do Now

Medicare’s Clinical Laboratory Fee Schedule (CLFS) resets on January 1, 2027. Under the Consolidated Appropriations Act, 2026, signed February 3, 2026, labs reported private payor rates from January 1 to June 30, 2025 during a May 1 to July 31, 2026 window. CMS released preliminary 2027 rates on September 22, 2026. About 1,171 codes are slated to fall, averaging roughly 16%, but any single code can drop no more than 15% per year in 2027, 2028 and 2029. Comments close October 21, 2026; final rates are expected in November.

Key Takeaways

  • Cuts are back. 2026 was a zero-cut year; 2027 is not.
  • 1,171 of 1,528 priced codes go down. 186 go up. 169 stay flat.
  • Molecular pathology (about 22%) and genomic sequencing (about 23%) take the hardest hits on average.
  • The 15% annual cap spreads deeper cuts across 2027 to 2029. It does not cancel them.
  • You have until October 21, 2026 to challenge preliminary rates with CMS.
  • Commercial contracts tied to a percentage of Medicare will feel this too, often on the same date.

If your lab bills Medicare Part B, the next twelve weeks matter more than the last three years. That’s not hype. After a run of congressional delays that started in 2020, the Protecting Access to Medicare Act (PAMA) cuts are scheduled to hit again on January 1, 2027, and this time CMS has fresh data behind them.

I’ve watched labs treat PAMA like weather: something that happens to you. That approach cost a lot of independent labs real money in 2018 through 2020. This guide walks through what changed in 2026, what the preliminary 2027 CLFS rates actually say, and the specific revenue cycle management moves independent and reference laboratories should make before the calendar flips.

What Changed With PAMA in 2026?

Quick history. PAMA, passed in 2014, told CMS to set CLFS rates using the weighted median of private payor rates that labs report. The first cycle used 2016 data and drove cuts from 2018 to 2020. The second cycle was supposed to follow, but Congress kept pushing it back. Labs were on the hook to report seven-year-old 2019 data by early 2026.

Then the Consolidated Appropriations Act, 2026 (H.R. 7148) was signed on February 3, 2026. It did three things that matter to you:

  1. It froze 2026: No CLFS payment reductions for calendar year 2026.
  2. It swapped the data: Labs reported private payor rates paid from January 1 through June 30, 2025, not 2019.
  3. It moved the reporting window: To May 1 through July 31, 2026, and capped any per-code reduction at 15% a year for 2027, 2028 and 2029.

The law also gave CMS room to adjust program details through guidance rather than full rulemaking. So keep an eye on CMS FAQs. They carry more weight than they used to.

What Do the Preliminary 2027 CLFS Rates Show?

CMS posted the preliminary CY 2027 rates on September 22, 2026. Of 1,947 applicable codes, 1,528 (about 78.5%) had enough private payor data to calculate a weighted median. The remaining 419 will be priced through crosswalking or gapfilling.

Here’s the split:

OutcomeNumber of HCPCS Codes
Rate decreases vs. 20261,171
Rate increases vs. 2026186
No change169
No comparable 2026 rate2
Total with weighted median data1,528
The averages by test category tell you where the pain lands:
Test CategoryAverage Preliminary Change
Genomic sequencingAbout −23%
Molecular pathologyAbout −22%
MicrobiologyAbout −19.3%
ImmunologyAbout −19.3%
ChemistryAbout −16%
Proprietary Laboratory Analyses (PLA)About −2.4%
All affected codes (overall)About −16%
Reporting also looked very different this time. In 2017, 1,942 laboratories reported. In 2026, CMS received data from 6,411 reporting labs, a jump of about 230%. Hospital lab participation rose from 21 to 875. That broader base is part of why the medians moved, and it’s why groups like the AHA and CAP have argued the data still doesn’t reflect the full commercial market. Medicare is projected to save roughly $1 billion a year from the reset.

How Does the 15% Annual Cap Actually Work?

This is where a lot of finance teams get tripped up. The cap limits how far a code can fall in one year. It doesn’t change where the rate ends up. If the weighted median is far below today’s rate, the cut just walks down over three years.

Take a test paid at $100 in 2026:

Weighted Median2027 Rate2028 Rate2029 Rate
$90$90.00$90.00$90.00
$78$85.00$78.00$78.00
$70$85.00$72.25$70.00
Look at the third row. A code headed for a 30% cut loses 15% in year one and keeps sliding. If your 2027 budget only models the first-year hit, you’re underestimating 2028 and 2029. Model all three years, code by code.
Find Out Where PAMA 2027 Is Hitting Your Lab.
Contact Us

Which Labs Are “Applicable Laboratories” Under PAMA?

Not every lab had to report. CMS uses three tests, and a lab has to meet all of them:

  • Lab type: An independent lab, a physician office lab, or a hospital outreach lab billing on its own NPI.
  • Majority of Medicare revenues: More than 50% of total Medicare revenues come from the CLFS and the Physician Fee Schedule combined.
  • Low expenditure threshold: At least $12,500 in Medicare CLFS revenue during the data collection period.

The reporting entity is the organization that files with the IRS under the TIN covering those labs. For multi-site reference lab networks, that usually means one corporate entity reporting for several NPIs. Getting that mapping wrong is one of the most common compliance gaps I see.

One more thing. PAMA allows civil monetary penalties for failing to report or for misrepresenting data, assessed per day of noncompliance (the statute sets up to $10,000 per day, adjusted for inflation). If you met the thresholds and didn’t report in the 2026 window, talk to counsel now. Don’t wait for CMS to find it.

What Independent & Reference Labs Must Do Now

Here’s the action list. It’s ordered by deadline, not by difficulty.

1. File Comments on Preliminary Rates Before October 21, 2026

This is the only shot you get to fix a bad number before it becomes your 2027 rate. Pull the preliminary file, find every code you run at volume, and compare the posted median to your own reported data. If a median looks wrong, say so, with evidence. Comments that show actual paid-claim data carry more weight than general objections. A trade group comment helps, but it won’t catch your specific code.

2. Build a Code-Level Revenue Exposure Model

Skip the blanket “we’ll lose 16%” assumption. Your exposure depends on your test mix. A lab heavy in chemistry panels looks nothing like a molecular reference lab. Pull 12 months of Medicare volume by CPT/HCPCS code, apply the preliminary 2027 rate, and then apply the capped 2028 and 2029 rates. Sort by dollar impact. Usually 20 to 40 codes drive most of the loss.

3. Check Your Commercial Contracts for Medicare-Linked Rates

Plenty of commercial and Medicare Advantage contracts pay a percentage of the Medicare fee schedule. When CLFS drops, those payments drop with it, often automatically on January 1. Pull every contract, flag the ones with Medicare-indexed language, and start renegotiation conversations before the new year. Payers rarely volunteer a fix.

4. Tighten Your Revenue Cycle to Close the Leakage

Lower rates leave less margin to absorb sloppy billing. Now’s the time to clean up:

  • Denial management: Track CARC/RARC trends by payer and test. Medical necessity denials (CARC 50) and missing information denials (CARC 16) are usually fixable at the front end.
  • Medical necessity documentation: Map your high-volume tests to the LCDs and NCDs your MAC enforces. Check ICD-10-CM pairing before the claim drops.
  • ABNs: Make sure Advance Beneficiary Notices are collected when coverage is uncertain. Without a valid ABN, that test is often a write-off.
  • Molecular billing: If you’re in a MolDX jurisdiction, confirm DEX Z-Codes and test registrations are current. Missing Z-Codes are a quiet source of denials.
  • Eligibility and prior authorization: Verify coverage and coordination of benefits up front, especially for genetic tests with commercial payers.
  • AR recovery: Work aged receivables before year-end. Cash in hand beats cash at 2027 rates.

Small recovery gains add up. A 3 to 5 point improvement in first-pass clean claim rate can offset a meaningful slice of a 15% cut on high-volume codes.

5. Review Your Test Menu and Pricing

Some tests won’t make sense at 2029 rates. Run cost-per-test against projected reimbursement for your bottom-margin codes. You may decide to send certain tests out, renegotiate reagent contracts, or consolidate platforms. For reference labs, this is also a good time to revisit client-bill pricing for hospital and physician clients, since many of those agreements reference Medicare too.

6. Get Ready for the Next Data Collection Cycle Now

Under the triennial structure, the 2027 to 2029 rates come from first-half 2025 data, and the next reporting round is expected in 2029 to set rates starting in 2030. That sounds far off. It isn’t. Your negotiated commercial rates in the next data period will shape what Medicare pays you after 2029. Labs that negotiated weak commercial rates in the past effectively voted for lower Medicare rates later. Build a clean, auditable process for capturing final paid amounts by HCPCS code, payer and volume, so next time is easier and more accurate.

7. Engage in Advocacy for the RESULTS Act

The RESULTS Act (H.R. 5269 / S. 2761) would change how CLFS rates are set, moving away from the current lab-reported model toward a more representative sample of commercial claims data. ACLA, CAP, ASCP, AHA and NILA have all pushed for it. It hasn’t passed. Until it does, the 15% annual cuts are the law. Contact your representatives, and give your trade association the code-level data it needs to make the case.

Independent Labs vs. Reference Labs: Where the Risk Differs

FactorIndependent / Regional LabsReference Labs
Biggest exposureHigh-volume routine chemistry and hematologyMolecular, genomic and esoteric testing
Payer mix riskHeavy Medicare reliance, thin marginsCommercial contracts often indexed to Medicare
Main leverDenial prevention and cost per testContract renegotiation and client-bill pricing
Compliance watchReporting thresholds and NPI mappingTIN-level reporting across multiple NPIs
Neither model is safe. A community lab running 80% Medicare volume on routine panels can feel a 15% hit right away. A reference lab might see smaller Medicare volume but bigger per-test drops on molecular codes, plus a knock-on effect in commercial contracts.

PAMA 2026 to 2029 Timeline at a Glance

DateMilestone
Feb 3, 2026Consolidated Appropriations Act, 2026 signed; 2026 cuts eliminated
Jan 1 to Jun 30, 2025Data collection period (private payor rates)
May 1 to Jul 31, 2026PAMA data reporting window
Sep 22, 2026CMS releases preliminary CY 2027 CLFS rates
Oct 21, 2026Deadline for comments on preliminary rates
November 2026Final CY 2027 CLFS rates expected
Jan 1, 2027New rates take effect; up to 15% cut per code
2028 and 2029Further reductions of up to 15% per code per year
2029Next PAMA reporting round expected, for rates starting 2030
Prepare Your Lab for the Coming Reset.
Contact Us

Frequently Asked Questions

When do the PAMA cuts take effect?
January 1, 2027. There were no CLFS reductions in 2026 under the Consolidated Appropriations Act, 2026. Reductions of up to 15% per code per year apply in 2027, 2028 and 2029.
Preliminary rates average about 16% lower across affected codes, but the statute caps any single code’s cut at 15% for 2027. Codes with deeper declines will keep falling in 2028 and 2029.
Applicable laboratories reported each HCPCS code, every private payor rate with final payment between January 1 and June 30, 2025, and the associated test volume. Reporting ran May 1 through July 31, 2026.
Yes, until October 21, 2026. Follow the comment instructions on the CMS CLFS page and include code-specific evidence, such as paid-claim data, whenever possible.
Indirectly, yes. Many commercial and Medicare Advantage contracts pay a percentage of Medicare rates, so CLFS cuts often flow straight into those payments unless the contract is renegotiated.
It’s proposed legislation (H.R. 5269 / S. 2761) that would reform how CLFS rates are calculated, using a broader sample of commercial claims data instead of relying only on lab-reported rates. As of October 2026 it has not been enacted.

The Bottom Line

PAMA 2027 isn’t a surprise anymore. The numbers are posted, the cap is set, and the comment window closes in a couple of weeks. Labs that file targeted comments, model exposure code by code, renegotiate Medicare-indexed contracts and tighten their revenue cycle will come out of 2027 in decent shape. Labs that wait for one more congressional delay are making a bet. Maybe it pays off. But it’s a risky way to run a lab.

If you’re not sure where your exposure sits, start with your top 30 Medicare codes by revenue. That one spreadsheet will tell you most of what you need to know.

Your Trusted Lab Billing Partner

Book Your Free Consultation

Book Consultation Today!

Book Consultation Today!